Free Trial
NASDAQ:ATAI

Atai Beckley Q1 2026 Earnings Results & Report

Atai Beckley logo

Atai Beckley beat analyst expectations on both earnings and revenue in its Q1 2026 results, released May 12, 2026. The company reported EPS of -$0.08 versus the -$0.11 consensus estimate, while revenue of $954 thousand topped the $217 thousand estimate by $737 thousand.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Atai Beckley EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.11
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Atai Beckley Revenue Results

Actual Revenue
$954 thousand
Expected Revenue
$217 thousand
Beat/Miss
Beat by +$737.00 thousand
YoY Revenue Growth
N/A

Upcoming Earnings

Atai Beckley's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules

Earnings Documents

Atai Beckley Q1 2026 Earnings FAQ

Atai Beckley (NASDAQ:ATAI) reported earnings of -$0.08 per share for Q1 2026, beating the consensus estimate of -$0.11. The report was announced on Tuesday, May 12, 2026.

Atai Beckley reported revenue of $954 thousand for Q1 2026, against a consensus estimate of $217 thousand.

Atai Beckley's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Atai Beckley on the company's earnings history page.

Atai Beckley Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Eli Lilly Completes Acquisition of AtaiBeckley
AtaiBeckley Inc.
See More Atai Beckley Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atai Beckley? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atai Beckley and other key companies, straight to your email.

About Atai Beckley

AtaiBeckley AG (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company developing psychedelic and other novel therapeutics for mental health conditions. The company was formed through the combination of atai Life Sciences and Beckley Psytech and focuses on treatments intended to address conditions such as depression, anxiety, post-traumatic stress disorder and substance-use disorders.

Its development programs include VLS-01, an investigational formulation of N,N-dimethyltryptamine (DMT), and BPL-003, an intranasal formulation of 5-MeO-DMT being studied for conditions including alcohol use disorder and depression. AtaiBeckley also evaluates non-psychedelic compounds and digital or technology-enabled treatment approaches intended to support the development and delivery of mental health therapies. Its products remain investigational and are not broadly approved for commercial use.

The company operates internationally, with activities and research programs spanning the United States and Europe. AtaiBeckley is led by co-founder and Chief Executive Officer Florian Brand. Beckley Psytech was founded by Amanda Feilding, whose work in psychedelic research and drug development contributed to the company’s combined platform.

View Atai Beckley Profile